|
1
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stiller CA, Bielack SS, Jundt G and
Steliarova-Foucher E: Bone tumours in European children and
adolescents, 1978–1997. Report from the Automated Childhood Cancer
Information System project. Eur J Cancer. 42:2124–2135. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fletcher CDM, Unni KK and Mertens F: World
Health Organization Classification of Tumours. Pathology and
Genetics of Tumours of Soft Tissue and Bone. IARC Press; Lyon:
2002
|
|
4
|
Ragland BD, Bell WC, Lopez RR and Siegal
GP: Cytogenetics and molecular biology of osteosarcoma. Lab Invest.
82:365–373. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bacci G, Longhi A, Fagioli F, Briccoli A,
Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for
osteosarcoma of the extremities: 27 year experience at Rizzoli
Institute, Italy. Eur J Cancer. 41:2836–2845. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weiss A, Khoury JD, Hoffer FA, Wu J,
Billups CA, Heck RK, Quintana J, Poe D, Rao BN and Daw NC:
Telangiectatic osteosarcoma: The St. Jude Children's Research
Hospital's experience. Cancer. 109:1627–1637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jaffe N, Carrasco H, Raymond K, Ayala A
and Eftekhari F: Can cure in patients with osteosarcoma be achieved
exclusively with chemotherapy and abrogation of surgery? Cancer.
95:2202–2210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mutsaers AJ and Walkley CR: Cells of
origin in osteosarcoma: Mesenchymal stem cells or osteoblast
committed cells? Bone. 62:56–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin PP, Pandey MK, Jin F, Raymond AK,
Akiyama H and Lozano G: Targeted mutation of p53 and Rb in
mesenchymal cells of the limb bud produces sarcomas in mice.
Carcinogenesis. 30:1789–1795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mutsaers AJ, Ng AJ, Baker EK, Russell MR,
Chalk AM, Wall M, Liddicoat BJ, Ho PW, Slavin JL, Goradia A, et al:
Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and
lineage-restricted transgenic shRNA. Bone. 55:166–178. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Overholtzer M, Rao PH, Favis R, Lu XY,
Elowitz MB, Barany F, Ladanyi M, Gorlick R and Levine AJ: The
presence of p53 mutations in human osteosarcomas correlates with
high levels of genomic instability. Proc Natl Acad Sci USA.
100:11547–11552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mohseny AB, Szuhai K, Romeo S, Buddingh
EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM and
Hogendoorn PC: Osteosarcoma originates from mesenchymal stem cells
in consequence of aneuploidization and genomic loss of Cdkn2. J
Pathol. 219:294–305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vilardaga JP, Romero G, Friedman PA and
Gardella TJ: Molecular basis of parathyroid hormone receptor
signaling and trafficking: A family B GPCR paradigm. Cell Mol Life
Sci. 68:1–13. 2011. View Article : Google Scholar
|
|
14
|
Huan J, Olgaard K, Nielsen LB and Lewin E:
Parathyroid hormone 7–84 induces hypocalcemia and inhibits the
parathyroid hormone 1–84 secretory response to hypocalcemia in rats
with intact parathyroid glands. J Am Soc Nephrol. 17:1923–1930.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheloha RW, Gellman SH, Vilardaga JP and
Gardella TJ: PTH receptor-1 signalling-mechanistic insights and
therapeutic prospects. Nat Rev Endocrinol. 11:712–724. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman PA and Goodman WG:
PTH(1-84)/PTH(7-84): A balance of power. Am J Physiol Renal
Physiol. 290:F975–F984. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burton DW, Brandt DW and Deftos LJ:
Parathyroid hormone-related protein in the cardiovascular system.
Endocrinology. 135:253–261. 1994.PubMed/NCBI
|
|
18
|
Kronenberg HM: Developmental regulation of
the growth plate. Nature. 423:332–336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abou-Samra AB, Jüppner H, Force T, Freeman
MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV and
Potts JT Jr: Expression cloning of a common receptor for
parathyroid hormone and parathyroid hormone-related peptide from
rat osteoblast-like cells: A single receptor stimulates
intracellular accumulation of both cAMP and inositol trisphosphates
and increases intracellular free calcium. Proc Natl Acad Sci USA.
89:2732–2736. 1992. View Article : Google Scholar
|
|
20
|
Mannstadt M, Jüppner H and Gardella TJ:
Receptors for PTH and PTHrP: Their biological importance and
functional properties. Am J Physiol. 277:F665–F675. 1999.PubMed/NCBI
|
|
21
|
Kondo H, Guo J and Bringhurst FR: Cyclic
adenosine monophosphate/protein kinase A mediates parathyroid
hormone/parathyroid hormone-related protein receptor regulation of
osteoclastogenesis and expression of RANKL and osteoprotegerin
mRNAs by marrow stromal cells. J Bone Miner Res. 17:1667–1679.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheung R, Erclik MS and Mitchell J:
Increased expression of G11alpha in osteoblastic cells enhances
parathyroid hormone activation of phospholipase C and AP-1
regulation of matrix metalloproteinase-13 mRNA. J Cell Physiol.
204:336–343. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rey A, Manen D, Rizzoli R, Ferrari SL and
Caverzasio J: Evidences for a role of p38 MAP kinase in the
stimulation of alkaline phosphatase and matrix mineralization
induced by parathyroid hormone in osteoblastic cells. Bone.
41:59–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferrari SL, Behar V, Chorev M, Rosenblatt
M and Bisello A: Endocytosis of ligand-human parathyroid hormone
receptor 1 complexes is protein kinase C-dependent and involves
beta-arrestin2. Real-time monitoring by fluorescence microscopy. J
Biol Chem. 274:29968–29975. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vilardaga JP, Krasel C, Chauvin S, Bambino
T, Lohse MJ and Nissenson RA: Internalization determinants of the
parathyroid hormone receptor differentially regulate
beta-arrestin/receptor association. J Biol Chem. 277:8121–8129.
2002. View Article : Google Scholar
|
|
26
|
De Camilli P, Emr SD, McPherson PS and
Novick P: Phosphoinositides as regulators in membrane traffic.
Science. 271:1533–1539. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vahle JL, Sato M, Long GG, Young JK,
Francis PC, Engelhardt JA, Westmore MS, Linda Y and Nold JB:
Skeletal changes in rats given daily subcutaneous injections of
recombinant human parathyroid hormone (1-34) for 2 years and
relevance to human safety. Toxicol Pathol. 30:312–321. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tashjian AH Jr and Gagel RF: Teriparatide
[human PTH(1-34)]: 2.5 years of experience on the use and safety of
the drug for the treatment of osteoporosis. J Bone Miner Res.
21:354–365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Watanabe A, Yoneyama S, Nakajima M, Sato
N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K,
Shimoi A, Yamatoya H, et al: Osteosarcoma in Sprague-Dawley rats
after long-term treatment with teriparatide (human parathyroid
hormone (1-34)). J Toxicol Sci. 37:617–629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Subbiah V, Madsen VS, Raymond AK, Benjamin
RS and Ludwig JA: Of mice and men: Divergent risks of
teriparatide-induced osteosarcoma. Osteoporos Int. 21:1041–1045.
2010. View Article : Google Scholar
|
|
31
|
Harper KD, Krege JH, Marcus R and Mitlak
BH: Comments on Initial experience with teriparatide in the United
States. Curr Med Res Opin. 22:19272006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harper KD, Krege JH, Marcus R and Mitlak
BH: Osteosarcoma and teriparatide? J Bone Miner Res. 22:3342007.
View Article : Google Scholar
|
|
33
|
Andrews EB, Gilsenan AW, Midkiff K,
Sherrill B, Wu Y, Mann BH and Masica D: The US postmarketing
surveillance study of adult osteosarcoma and teriparatide: Study
design and findings from the first 7 years. J Bone Miner Res.
27:2429–2437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ho PW, Goradia A, Russell MR, Chalk AM,
Milley KM, Baker EK, Danks JA, Slavin JL, Walia M, Crimeen-Irwin B,
et al: Knockdown of PTHR1 in osteosarcoma cells decreases invasion
and growth and increases tumor differentiation in vivo. Oncogene.
34:2922–2933. 2015. View Article : Google Scholar
|
|
35
|
Yang D, Singh R, Divieti P, Guo J,
Bouxsein ML and Bringhurst FR: Contributions of parathyroid hormone
(PTH)/PTH-related peptide receptor signaling pathways to the
anabolic effect of PTH on bone. Bone. 40:1453–1461. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ardura JA, Wang B, Watkins SC, Vilardaga
JP and Friedman PA: Dynamic Na+–H+ exchanger regulatory factor-1
association and dissociation regulate parathyroid hormone receptor
trafficking at membrane microdomains. J Biol Chem. 286:35020–35029.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kawane T, Mimura J, Yanagawa T,
Fujii-Kuriyama Y and Horiuchi N: Parathyroid hormone (PTH)
down-regulates PTH/PTH-related protein receptor gene expression in
UMR-106 osteoblast-like cells via a 3′,5′-cyclic adenosine
mono-phosphate-dependent, protein kinase A-independent pathway. J
Endocrinol. 178:247–256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Evans DB, Hipskind RA and Bilbe G:
Analysis of signaling pathways used by parathyroid hormone to
activate the c-fos gene in human SaOS2 osteoblast-like cells. J
Bone Miner Res. 11:1066–1074. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pearman AT, Chou WY, Bergman KD, Pulumati
MR and Partridge NC: Parathyroid hormone induces c-fos promoter
activity in osteoblastic cells through phosphorylated cAMP response
element (CRE)-binding protein binding to the major CRE. J Biol
Chem. 271:25715–25721. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liao J and McCauley LK: Skeletal
metastasis: Established and emerging roles of parathyroid hormone
related protein (PTHrP). Cancer Metastasis Rev. 25:559–571. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pasquini GM, Davey RA, Ho PW, Michelangeli
VP, Grill V, Kaczmarczyk SJ and Zajac JD: Local secretion of
parathyroid hormone-related protein by an osteoblastic osteosarcoma
(UMR 106-01) cell line results in growth inhibition. Bone.
31:598–605. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
García-Martín A, Acitores A, Maycas M,
Villanueva-Peñacarrillo ML and Esbrit P: Src kinases mediate VEGFR2
transactivation by the osteostatin domain of PTHrP to modulate
osteoblastic function. J Cell Biochem. 114:1404–1413. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jemtland R, Rian E, Olstad OK, Haug E,
Bruland OS, Bucht E and Gautvik KM: Two human osteoblast-like
osteosarcoma cell lines show distinct expression and differential
regulation of parathyroid hormone-related protein. J Bone Miner
Res. 14:904–914. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gagiannis S, Müller M, Uhlemann S, Koch A,
Melino G, Krammer PH, Nawroth PP, Brune M and Schilling T:
Parathyroid hormone-related protein confers chemoresistance by
blocking apoptosis signaling via death receptors and mitochondria.
Int J Cancer. 125:1551–1557. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kresse H and Schönherr E: Proteoglycans of
the extracellular matrix and growth control. J Cell Physiol.
189:266–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Afratis N, Gialeli C, Nikitovic D,
Tsegenidis T, Karousou E, Theocharis AD, Pavão MS, Tzanakakis GN
and Karamanos NK: Glycosaminoglycans: Key players in cancer cell
biology and treatment. FEBS J. 279:1177–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sanderson RD, Yang Y, Suva LJ and Kelly T:
Heparan sulfate proteoglycans and heparanase - partners in
osteolytic tumor growth and metastasis. Matrix Biol. 23:341–352.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Maxwell CA, McCarthy J and Turley E:
Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual
oncogenic functions? J Cell Sci. 121:925–932. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu R, Boudreau A and Bissell MJ: Tissue
architecture and function: Dynamic reciprocity via extra- and
intra-cellular matrices. Cancer Metastasis Rev. 28:167–176. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kouvidi K, Nikitovic D, Berdiaki A and
Tzanakakis GN: Hyaluronan/RHAMM interactions in mesenchymal tumor
pathogenesis: Role of growth factors. Adv Cancer Res. 123:319–349.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nikitovic D, Chalkiadaki G, Berdiaki A,
Aggelidakis J, Katonis P, Karamanos NK and Tzanakakis GN: Lumican
regulates osteosarcoma cell adhesion by modulating TGFβ2 activity.
Int J Biochem Cell Biol. 43:928–935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Unni KK: Osteosarcoma of bone. J Orthop
Sci. 3:287–294. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Benayahu D, Shur I, Marom R, Meller I and
Issakov J: Cellular and molecular properties associated with
osteosarcoma cells. J Cell Biochem. 84:108–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nikitovic D, Tsatsakis AM, Karamanos NK
and Tzanakakis GN: The effects of genistein on the synthesis and
distribution of glycosaminoglycans/proteoglycans by two
osteosarcoma cell lines depends on tyrosine kinase and the estrogen
receptor density. Anticancer Res. 23(1A): 459–464. 2003.PubMed/NCBI
|
|
55
|
Nikitovic D, Zafiropoulos A, Katonis P,
Tsatsakis A, Theocharis AD, Karamanos NK and Tzanakakis GN:
Transforming growth factor-beta as a key molecule triggering the
expression of versican isoforms v0 and v1, hyaluronan synthase-2
and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB
Life. 58:47–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nikitovic D, Berdiaki K, Chalkiadaki G,
Karamanos N and Tzanakakis G: The role of SLRP-proteoglycans in
osteosarcoma pathogenesis. Connect Tissue Res. 49:235–238. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nikitovic D, Aggelidakis J, Young MF,
Iozzo RV, Karamanos NK and Tzanakakis GN: The biology of small
leucine-rich proteoglycans in bone pathophysiology. J Biol Chem.
287:33926–33933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Datta NS and Abou-Samra AB: PTH and PTHrP
signaling in osteoblasts. Cell Signal. 21:1245–1254. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sabbieti MG, Agas D, Xiao L, Marchetti L,
Coffin JD, Doetschman T and Hurley MM: Endogenous FGF-2 is
critically important in PTH anabolic effects on bone. J Cell
Physiol. 219:143–151. 2009. View Article : Google Scholar :
|
|
60
|
Teplyuk NM, Haupt LM, Ling L, Dombrowski
C, Mun FK, Nathan SS, Lian JB, Stein JL, Stein GS, Cool SM, et al:
The osteogenic transcription factor Runx2 regulates components of
the fibroblast growth factor/proteoglycan signaling axis in
osteoblasts. J Cell Biochem. 107:144–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Datsis GA, Berdiaki A, Nikitovic D,
Mytilineou M, Katonis P, Karamanos NK and Tzanakakis GN:
Parathyroid hormone affects the fibroblast growth
factor-proteoglycan signaling axis to regulate osteosarcoma cell
migration. FEBS J. 278:3782–3792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zafiropoulos A, Nikitovic D, Katonis P,
Tsatsakis A, Karamanos NK and Tzanakakis GN: Decorin-induced growth
inhibition is overcome through protracted expression and activation
of epidermal growth factor receptors in osteosarcoma cells. Mol
Cancer Res. 6:785–794. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Nikitovic D, Zafiropoulos A, Tzanakakis
GN, Karamanos NK and Tsatsakis AM: Effects of glycosaminoglycans on
cell proliferation of normal osteoblasts and human osteosarcoma
cells depend on their type and fine chemical compositions.
Anticancer Res. 25:2851–2856. 2005.PubMed/NCBI
|
|
64
|
El Khassawna T, Böcker W, Brodsky K,
Weisweiler D, Govindarajan P, Kampschulte M, Thormann U, Henss A,
Rohnke M and Bauer N: Impaired extracellular matrix structure
resulting from malnutrition in ovariectomized mature rats.
Histochem Cell Biol. 144:491–507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang X, Harimoto K, Xie S, Cheng H, Liu J
and Wang Z: Matrix protein biglycan induces osteoblast
differentiation through extracellular signal-regulated kinase and
Smad pathways. Biol Pharm Bull. 33:1891–1897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ruan K, Bao S and Ouyang G: The
multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci.
66:2219–2230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fortunati D, Reppe S, Fjeldheim AK,
Nielsen M, Gautvik VT and Gautvik KM: Periostin is a collagen
associated bone matrix protein regulated by parathyroid hormone.
Matrix Biol. 29:594–601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nikitovic D, Kouvidi K, Kavasi RM,
Berdiaki A and Tzanakakis GN: Hyaluronan/Hyaladherins - a Promising
Axis for Targeted Drug Delivery in Cancer. Curr Drug Deliv.
13:500–511. 2016. View Article : Google Scholar
|
|
69
|
Midura RJ, Evanko SP and Hascall VC:
Parathyroid hormone stimulates hyaluronan synthesis in an
osteoblast-like cell line. J Biol Chem. 269:13200–13206.
1994.PubMed/NCBI
|
|
70
|
Midura RJ, Su X, Morcuende JA, Tammi M and
Tammi R: Parathyroid hormone rapidly stimulates hyaluronan
synthesis by periosteal osteoblasts in the tibial diaphysis of the
growing rat. J Biol Chem. 278:51462–51468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Berdiaki A, Datsis GA, Nikitovic D,
Tsatsakis A, Katonis P, Karamanos NK and Tzanakakis GN: Parathyroid
hormone (PTH) peptides through the regulation of hyaluronan
metabolism affect osteosarcoma cell migration. IUBMB Life.
62:377–386. 2010.PubMed/NCBI
|
|
72
|
Pacheco-Costa R, Campos JF, Katchburian E,
de Medeiros VP, Nader HB, Nonaka KO, Plotkin LI and Reginato RD:
Modifications in bone matrix of estrogen-deficient rats treated
with intermittent PTH. BioMed Res Int. 2015:4541622015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kido A, Tsutsumi M, Iki K, Takahama M,
Tsujiuchi T, Morishita T, Tamai S and Konishi Y: Overexpression of
matrix metalloproteinase (MMP)-9 correlates with metastatic potency
of spontaneous and 4-hydroxyaminoquinoline 1-oxide (4-HAQO)-induced
transplantable osteosarcomas in rats. Cancer Lett. 137:209–216.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang J, Shi Q, Yuan TX, Song QL, Zhang Y,
Wei Q, Zhou L, Luo J, Zuo G, Tang M, et al: Matrix
metalloproteinase 9 (MMP-9) in osteosarcoma: Review and
meta-analysis. Clin Chim Acta. 433:225–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Husmann K, Arlt MJ, Muff R, Langsam B,
Bertz J, Born W and Fuchs B: Matrix Metalloproteinase 1 promotes
tumor formation and lung metastasis in an intratibial injection
osteosarcoma mouse model. Biochim Biophys Acta. 1832:347–354. 2013.
View Article : Google Scholar
|
|
77
|
Egeblad M and Werb Z: New functions for
the matrix metal-loproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shuman Moss LA, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: Changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Uchibori M, Nishida Y, Nagasaka T, Yamada
Y, Nakanishi K and Ishiguro N: Increased expression of
membrane-type matrix metalloproteinase-1 is correlated with poor
prognosis in patients with osteosarcoma. Int J Oncol. 28:33–42.
2006.
|
|
80
|
Himelstein BP, Asada N, Carlton MR and
Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in
childhood osseous osteosarcoma. Med Pediatr Oncol. 31:471–474.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kimura R, Ishikawa C, Rokkaku T, Janknecht
R and Mori N: Phosphorylated c-Jun and Fra-1 induce matrix
metallopro-teinase-1 and thereby regulate invasion activity of 143B
osteosarcoma cells. Biochim Biophys Acta. 1813:1543–1553. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Lee M and Partridge NC: Parathyroid
hormone activation of matrix metalloproteinase-13 transcription
requires the histone acetyltransferase activity of p300 and PCAF
and p300-dependent acetylation of PCAF. J Biol Chem.
285:38014–38022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhu W, Yang ML, Yang GY, Boden G and Li L:
Changes in serum runt-related transcription factor 2 levels after a
6-month treatment with recombinant human parathyroid hormone in
patients with osteoporosis. J Endocrinol Invest. 35:602–606.
2012.
|
